Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Centessa Pharmaceuticals plc before investing.

In this article, we go over a few key elements for understanding Centessa Pharmaceuticals plc’s stock price such as:

• Centessa Pharmaceuticals plc’s current stock price and volume
• Why Centessa Pharmaceuticals plc’s stock price changed recently
• Upgrades and downgrades for CNTA from analysts
• CNTA’s stock price momentum as measured by its relative strength

About Centessa Pharmaceuticals plc (CNTA)

Before we jump into Centessa Pharmaceuticals plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Want to learn more about Centessa Pharmaceuticals plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Centessa Pharmaceuticals plc.

Centessa Pharmaceuticals plc’s Stock Price as of Market Close

As of May 20, 2025, 12:43 PM, CST, Centessa Pharmaceuticals plc’s stock price was $12.605.

Centessa Pharmaceuticals plc is up 2.81% from its previous closing price of $12.260.

During the last market session, Centessa Pharmaceuticals plc’s stock traded between $12.200 and $13.210. Currently, there are approximately 133.03 million shares outstanding for Centessa Pharmaceuticals plc.

Centessa Pharmaceuticals plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Centessa Pharmaceuticals plc Stock Price History

Centessa Pharmaceuticals plc’s (CNTA) price is currently down 8.06% so far this month.

During the month of May, Centessa Pharmaceuticals plc’s stock price has reached a high of $14.390 and a low of $11.820.

Over the last year, Centessa Pharmaceuticals plc has hit prices as high as $19.090 and as low as $7.750. Year to date, Centessa Pharmaceuticals plc’s stock is down 24.75%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Centessa Pharmaceuticals plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 19, 2025, there was 1 analyst who downgraded Centessa Pharmaceuticals plc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Centessa Pharmaceuticals plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Centessa Pharmaceuticals plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Centessa Pharmaceuticals plc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Centessa Pharmaceuticals plc (CNTA) by visiting AAII Stock Evaluator.

Relative Price Strength of Centessa Pharmaceuticals plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 19, 2025, Centessa Pharmaceuticals plc has a weighted four-quarter relative price strength of 2.16%, which translates to a Momentum Score of 67 and is considered to be Strong.

Want to learn more about how Centessa Pharmaceuticals plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Centessa Pharmaceuticals plc Stock Price: Bottom Line

As of May 20, 2025, Centessa Pharmaceuticals plc’s stock price is $12.605, which is up 2.81% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Centessa Pharmaceuticals plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.